NOVOZYMES NORTH IOR supplier risk profile Q1 2026: 74 shipments, Denmark-focused sourcing, compliance overview.
NOVOZYMES NORTH IOR recorded 74 shipments in Q1 2026 across 4 suppliers and 2 source countries. Denmark dominated the import profile with 70 shipments (94.6% share), led by parent company NOVOZYMES and contract manufacturer DANPAL PRODUKTION APS. A secondary sourcing stream of 4 shipments arrived from China via NOVOZYMES Biotechnology and a NOVOZYMES entity. No HS classification data was provided for this shipment set.
Trigram screen against OFAC SDN, BIS Entity List, UFLPA Entity List, SAM Exclusions, EU FSF, UK HMT, UN SC, and 25+ allied jurisdictions.
Distance-screened against all 380 facilities in the ASPI Xinjiang Data Project. Proximity score: 100 / 100.
No sanctions watchlist matches were flagged for NOVOZYMES NORTH IOR in Q1 2026. No suppliers registered exposure under UFLPA forced-labor risk criteria. The importer carries an overall risk score of 75 (grade B).
4 distinct tier-1 suppliers in Q1 2026
| NOVOZYMES | Denmark | 64 |
| DANPAL PRODUKTION APS | Denmark | 6 |
| NOVOZYMES BIOTECHNOLOGY | China | 3 |
| NOVOZYMES | China | 1 |
Share of Q1 2026 inbound shipments by source country
0 tier-2 + 0 tier-3 nodes mapped - sign up to see them.
Free Tarifflo account unlocks the complete tier 1 / 2 / 3 supplier graph, daily refresh, alerts, and sanctions + UFLPA monitoring on every shipment.